Kytopen

📍 Cambridge, United States🗓 Founded 2017👥 37 employees💰 Last funded Jan 2024
Biotechnology Research🌐 kytopen.com
Website LinkedIn
Kytopen is focused on the development and commercialization of groundbreaking genome engineering platforms for expediting the discovery, development, and manufacture of gene-modified cell therapies. Developed at MIT, the Flowfect® platform, harmonizing microfluidics and automation, revolutionizes the delivery of genome engineering materials to cells of therapeutic interest in an expeditious, scalable, and economically advantageous manner compared to current alternatives. In May 2023, Kytopen unveiled the Flowfect Discover™, an automated high-throughput genome engineering platform, and disclosed strategic partnerships with industry-leading Contract Development and Manufacturing Organizations (CDMOs) and translational academic medical centers. By combining Flowfect Discover™ with the Flowfect Tx™ large-scale delivery device in process development workflows, developers can now surmount manufacturing challenges during the discovery stage, fostering swifter and more cost-effective innovation.
6
Total investors
3
Early stage
2
Mid stage
1
Late stage
2017
Founded

Investors

6 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
5
Hong Kong SAR
1
Investor activity2019–2024 · investors recorded per year
20193202012021120241
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Kytopen?
Kytopen has 6 investors on record on gritt.io, including 3 early-stage backers, 2 mid-stage and 1 late-stage investors.
When did Kytopen last raise funding?
The most recent investment in Kytopen recorded on gritt.io was in January 2024.
When was Kytopen founded?
Kytopen was founded in 2017.
What industry is Kytopen in?
Kytopen operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Kytopen based?
Kytopen is headquartered in Cambridge, United States.